MSB 2.03% $1.45 mesoblast limited

Cell Therapy News/Articles, page-10446

  1. 100 Posts.
    lightbulb Created with Sketch. 65
    Not sure if this was posted prior.
    From Feb 2021.

    Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons

    https://hotcopper.com.au/data/attachments/3458/3458603-0b23b96a1a0b2107ef434826f06d7d5d.jpg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.